1-(4-bromo-2,6-dimethylphenyl)-7-methyl-5-pentan-3-yloxy-2H-pyrido[2,3-d][1,3]oxazin-4-one

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-(4-bromo-2,6-dimethylphenyl)-7-methyl-5-pentan-3-yloxy-2H-pyrido[2,3-d][1,3]oxazin-4-one
• 化学式: C₂₁H₂₅BrN₂O₃
• 分子量: 433.3
• InChiKey: GYPQSNBMZWFUDI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.2
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  51.7
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues
  申请人：Pfizer Products Inc.

  公开号：EP1149583A2

  公开（公告）日：2001-10-31

  This invention is directed to pharmaceutical compositions comprising corticotropin releasing factor antagonist and growth hormone or growth hormone secretagogues, prodrugs thereof, or pharmaceutically acceptable salts of said compounds or said prodrugs. The invention is also directed to the use of such compositions in the treatment or prevention of osteoporosis and heart-related diseases (including congestive heart failure) in mammals, particularly humans.

  本发明涉及包含促肾上腺皮质激素释放因子拮抗剂和生长激素或生长激素促泌剂、其原药或所述化合物或所述原药的药学上可接受的盐的药物组合物。本发明还用于治疗或预防哺乳动物，特别是人类的骨质疏松症和心脏相关疾病（包括充血性心力衰竭）。
• Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues
  申请人：——

  公开号：US20010041673A1

  公开（公告）日：2001-11-15

  This invention is directed to pharmaceutical compositions comprising corticotropin releasing factor antagonist and growth hormone or growth hormone secretagogues, prodrugs thereof, or pharmaceutically acceptable salts of said compounds or said prodrugs. The invention is also directed to methods of treating heart related diseases (including congestive heart failure) in mammals, and particularly in humans.

  本发明涉及包含促肾上腺皮质激素释放因子拮抗剂和生长激素或生长激素促泌剂、其原药或所述化合物或所述原药的药学上可接受的盐的药物组合物。本发明还涉及治疗哺乳动物，特别是人类心脏相关疾病（包括充血性心力衰竭）的方法。
• Use of CRF antagonists and related compositions
  申请人：Pfizer Inc.

  公开号：US20020156089A1

  公开（公告）日：2002-10-24

  A corticotropin releasing factor (CRF) antagonist is administered to treat a condition selected from the group consisting of: c) disorders that can be treated by altering circadian rhythm; and d) depression, further wherein a second compound for treating depression is administered, the second compound for treating depression having an onset of action that is delayed with respect to that of the CRF antagonist.

  一种促肾上腺皮质激素释放因子（CRF）拮抗剂用于治疗选自以下组别的疾病： c) 可通过改变昼夜节律来治疗的疾病；以及 d) 抑郁症，其中还施用了治疗抑郁症的第二种化合物，治疗抑郁症的第二种化合物的起效时间相对于 CRF 拮抗剂的起效时间有所延迟。
• Use of corticotropin releasing factor antagonists and related compositions
  申请人：——

  公开号：US20030199527A1

  公开（公告）日：2003-10-23

  The present invention relates to compositions and methods of achieving a therapeutic effect including, the treatment or prevention of Syndrome X in an animal, preferably a mammal including a human subject or a companion animal, using a corticotropin releasing factor (CRF) antagonist alone or together with a glucocorticoid receptor antagonist.

  本发明涉及单独使用促肾上腺皮质激素释放因子（CRF）拮抗剂或与糖皮质激素受体拮抗剂一起使用以达到治疗效果的组合物和方法，包括治疗或预防动物（最好是哺乳动物，包括人或伴侣动物）的 X 综合征。
• Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists
  申请人：Romano Steve

  公开号：US20050209250A1

  公开（公告）日：2005-09-22

  The present invention is directed to a pharmaceutical compositions for treating, for example, mood disorders or conditions, psychotic disorders or conditions, or a combination thereof, in a mammal such as a human, the composition comprising (a) an atypical antipsychotic, a prodrug thereof or a pharmaceutically acceptable salt of the atypical antipsychotic or prodrug thereof, (b) a corticotropin releasing factor antagonist, a prodrug thereof, or pharmaceutically acceptable salt of said corticotropin releasing factor antagonist or prodrug thereof, and optionally (c) a pharmaceutically acceptable vehicle, carrier or diluent. The present invention is also directed to a method for treating one or more disorders or conditions described in the previous sentence, the method comprising administering to a mammal in need of such treatment components (a) and (b) described in the previous sentence, wherein (a) and (b) are each optionally and independently administered together with a pharmaceutically acceptable vehicle, carrier or diluent.

  本发明涉及一种药物组合物，用于治疗哺乳动物（例如人类）的情绪障碍或病症、精神病性障碍或病症或其组合，该组合物包含(a)非典型抗精神病药、其原药或非典型抗精神病药或其原药的药学上可接受的盐；(b) 促肾上腺皮质激素释放因子拮抗剂、其原药或所述促肾上腺皮质激素释放因子拮抗剂或其原药的药学上可接受的盐；以及任选 (c) 药学上可接受的载体、载体或稀释剂。本发明还涉及一种治疗前一句所述的一种或多种疾病或病症的方法，该方法包括对需要这种治疗的哺乳动物施用前一句所述的成分(a)和(b)，其中(a)和(b)可选择地各自独立地与药学上可接受的载体、载体或稀释剂一起施用。